Paper39267682
Nrf2 in human cancers: biological significance and therapeutic potential.
Tian Y and 4 others. Am J Cancer Res, 2024. Cited by 9 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Nrf2 in human cancers: biological significance and therapeutic potential. Papers, record 39267682. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39267682
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References246
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36829256 | Functions and mechanisms of lncRNA MALAT1 in cancer chemotherapy resistance. | Biomark Res | 2023 | https://conductscience.org/library/papers/36829256 | PubMed |
| 2 | 36823108 | Ibrutinib facilitates the sensitivity of colorectal cancer cells to ferroptosis through BTK/NRF2 pathway. | Cell Death Dis | 2023 | https://conductscience.org/library/papers/36823108 | PubMed |
| 3 | 36791159 | Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer. | N Engl J Med | 2023 | https://conductscience.org/library/papers/36791159 | PubMed |
| 4 | 11303500 | Pro-inflammatory programmed cell death. | Trends Microbiol | 2001 | https://conductscience.org/library/papers/11303500 | PubMed |
| 5 | 36909174 | Wogonin induces ferroptosis in pancreatic cancer cells by inhibiting the Nrf2/GPX4 axis. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/36909174 | PubMed |
| 6 | 30339884 | Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer. | Free Radic Biol Med | 2018 | https://conductscience.org/library/papers/30339884 | PubMed |
| 7 | 36453238 | Triptolide promotes ferroptosis by suppressing Nrf2 to overcome leukemia cell resistance to doxorubicin. | Mol Med Rep | 2023 | https://conductscience.org/library/papers/36453238 | PubMed |
| 8 | 19967722 | Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. | J Pathol | 2010 | https://conductscience.org/library/papers/19967722 | PubMed |
| 9 | 36948284 | Doxorubicin-loaded micelles in tumor cell-specific chemotherapy. | Environ Res | 2023 | https://conductscience.org/library/papers/36948284 | PubMed |
| 10 | 35214073 | Ultrasound-Responsive Nrf2-Targeting siRNA-Loaded Nanobubbles for Enhancing the Treatment of Melanoma. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/35214073 | PubMed |
| 11 | 26341193 | Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach. | Drug Resist Updat | 2015 | https://conductscience.org/library/papers/26341193 | PubMed |
| 12 | 24011591 | Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy. | Mol Cell | 2013 | https://conductscience.org/library/papers/24011591 | PubMed |
| 13 | 32319188 | β-Sitosterol-assisted silver nanoparticles activates Nrf2 and triggers mitochondrial apoptosis via oxidative stress in human hepatocellular cancer cell line. | J Biomed Mater Res A | 2020 | https://conductscience.org/library/papers/32319188 | PubMed |
| 14 | 36933639 | Harnessing function of EMT in hepatocellular carcinoma: From biological view to nanotechnological standpoint. | Environ Res | 2023 | https://conductscience.org/library/papers/36933639 | PubMed |
| 15 | 36715963 | Adipokines and epithelial-mesenchymal transition (EMT) in cancer. | Mol Cell Biochem | 2023 | https://conductscience.org/library/papers/36715963 | PubMed |
| 16 | 33393215 | MOAP-1-mediated dissociation of p62/SQSTM1 bodies releases Keap1 and suppresses Nrf2 signaling. | EMBO Rep | 2021 | https://conductscience.org/library/papers/33393215 | PubMed |
| 17 | 32274363 | Overexpression of Nrf2 promotes colon cancer progression via ERK and AKT signaling pathways. | Ann Surg Treat Res | 2020 | https://conductscience.org/library/papers/32274363 | PubMed |
| 18 | 35011574 | miR-140-5p Attenuates Hypoxia-Induced Breast Cancer Progression by Targeting Nrf2/HO-1 Axis in a Keap1-Independent Mechanism. | Cells | 2021 | https://conductscience.org/library/papers/35011574 | PubMed |
| 19 | 33416106 | ROS‑mediated hypomethylation of PRDX5 promotes STAT3 binding and activates the Nrf2 signaling pathway in NSCLC. | Int J Mol Med | 2021 | https://conductscience.org/library/papers/33416106 | PubMed |
| 20 | 26122708 | Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease. | Free Radic Biol Med | 2015 | https://conductscience.org/library/papers/26122708 | PubMed |
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42797750 | Neodymium Nitrate Suppresses Malignant Phenotypes in Hep-G2 Cells by Targeting Nrf2 to Inhibit EMT and Induce Ferroptosis. | Toxics | 2026 | https://conductscience.org/library/papers/42797750 | PubMed |
| 41656817 | [Role and mechanisms of FoxO3a-related signaling pathways in breast cancer cell apoptosis]. | Zhong Nan Da Xue Xue Bao Yi Xue Ban | 2025 | https://conductscience.org/library/papers/41656817 | PubMed |
| 41470226 | Effects of the Pharmacological Modulation of NRF2 in Cancer Progression. | Medicina (Kaunas) | 2025 | https://conductscience.org/library/papers/41470226 | PubMed |
| 41301693 | The Role of Mitochondrial Genome Stability and Metabolic Plasticity in Thyroid Cancer. | Biomedicines | 2025 | https://conductscience.org/library/papers/41301693 | PubMed |
| 40940829 | Targeting Cancer Translational Plasticity: IRES-Driven Metabolism and Survival Within the Tumor Microenvironment. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40940829 | PubMed |
| 40732256 | Bardoxolone Methyl: A Comprehensive Review of Its Role as a Nrf2 Activator in Anticancer Therapeutic Applications. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40732256 | PubMed |
| 40649894 | Repurposing Dimethyl Fumarate Targeting Nrf2 to Slow Down the Growth of Areas of Geographic Atrophy. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40649894 | PubMed |
| 39940878 | Ligustrazine hydrochloride Prevents Ferroptosis by Activating the NRF2 Signaling Pathway in a High-Altitude Cerebral Edema Rat Model. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/39940878 | PubMed |
| 39872524 | Top 100 most-cited articles on apoptosis of non-small cell lung cancer over the past two decades: a bibliometrics analysis. | Front Immunol | 2024 | https://conductscience.org/library/papers/39872524 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| NFE2L2 | 4780 | PubTator's text mining | https://conductscience.org/library/genes/4780 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39267682
GET https://conductscience.org/api/papers/v1/39267682/references?page=2